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Abstract
Introduction
Ewing sarcoma (ES) family of tumors is one of the most common groups of malignancies arising
in children, adolescents, and young adults. Although characteristic histology with
immunohistochemical expression of CD99 and FLI1 after exclusion of other small round blue
cell tumors is considered diagnostic of ES, frequency of typical ES translocation, i.e., t(11;22)
(q24;q12) is not known in our population. Therefore, in this study, we aimed to evaluate the
frequency of this translocation in histologically and immunohistochemically diagnosed cases
of ES along with its association with other pathological parameters.
Methods
A total of 43 morphologically and immunohistochemically diagnosed cases of ES were included
in the study. Fluorescence in situ hybridization (FISH) was performed on representative
paraffin blocks to identify t(11;22)(q24;q12) translocation. Association with various
clinicopathological characteristics was determined.
Results
Mean age of the patients was 18.23±9.57 years. Bone was the most commonly involved site (22;
51.2%) followed by soft tissue (17; 39.5%) and parenchymal organs (4; 9.3%). A total of 88.4% of
cases were found to be FISH-positive for t(11;22)(q24;q12). No significant association of
translocation positive cases was noted with tumor size or disease-free survival. Similarly, no
significant association of tumor size with disease-free survival was found.
Conclusions
A significant proportion of cases of histologically diagnosed cases of ES exhibited characteristic
t(11;22)(q24;q12). This signifies that histology along with immunohistochemistry is reliable for
the diagnosis of this tumor; however, in difficult cases, FISH can be performed to detect
characteristic translocation. Moreover, we did not find tumor size to be a significant prognostic
indicator of survival in ES.
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Introduction
Ewing’s sarcoma (ES), also referred to as primitive neuroectodermal tumor, is one of the most
common mesenchymal tumors in children and young adults that can occur in both bones and
soft tissues [1]. The tumor was named after James Ewing, an American pathologist, who first
described this disease in 1921 [2]. ES accounts for approximately 6% to 10% of malignant bone
tumors and is the second most common malignant bone tumor of children and young adults.
Histologically, the tumor is uniformly composed of sheets of closely packed small round cells.
Glycogen granules are demonstrated in the cytoplasm by periodic acid-Schiff (PAS) stain.
Immunohistochemically, ES are positive for vimentin, MIC-2 gene product (CD99), and FLI1.
The differential diagnosis of ES is wide, including malignant lymphoma, especially
lymphoblastic lymphoma, neuroblastoma, rhabdomyosarcoma, desmoplastic small round cell
tumor, and small cell osteosarcoma [3]. However, the diagnosis is reached in most cases only
with the help of immunohistochemistry (IHC). On the other hand, some cases require molecular
studies for the confirmation of the diagnosis. More than 90% ES cases have the t(11;22)
chromosomal translocation. The identification of the highly specific balanced chromosomal
rearrangement t(11;22)(q24;q12) in most ESs provides a valuable tool for diagnosing this tumor
at the molecular level [4,5].
Chromosomal analysis of ES has advanced further with the development of fluorescence in situ
hybridization (FISH) that can be applied to formalin-fixed paraffin-embedded tumor tissue,
sparing the need of fresh frozen tissue. Moreover, FISH is found to be more sensitive and
specific compared to reverse transcriptase-polymerase chain reaction (RT-PCR) on formalin-
embedded tissue sections [6]. In resource-limited countries like Pakistan, FISH cannot be
performed on every suspected case of ES for diagnostic confirmation, and we do not even know
the frequency of this translocation in our population. Therefore, in this study, we aimed to
evaluate the frequency of t(11;22)(q24;q12) in histologically and immunohistochemically
diagnosed cases of ES.
Materials And Methods
This is a retrospective observational study conducted at Aga Khan University Hospital’s
Histopathology Department over a period of two years, involving 43 morphologically and
immunohistochemically diagnosed cases of ES. All cases were excision specimens. Cases with
suggestive but not conclusive diagnosis of ES and specimens sent without formalin (without
proper fixation leading to loss of cellular details) were excluded from the study. The specimens
were macroscopically examined according to the established guidelines. The sections were
stained with hematoxylin and eosin (H&E) and PAS, along with a panel of
immunohistochemical stains including vimentin, MIC2 (CD99), LCA, TdT, synaptophysin, FLI1,
CKAE1/AE3, myogenin, and desmin, as shown in Figure 1.
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FIGURE 1: (A) H&E section on 400X showing small round blue
cell tumor. (B) Tumor cells showing cytoplasmic glycogen
positivity on PAS stain. (C) Tumor cells showing CD99
immunopositivity. (D) Tumor cells negative with desmin
immunostain.
H&E, hematoxylin and eosin; PAS, periodic acid-Schiff
FISH was performed on representative paraffin blocks using LSI EWSR1 Dual Color Break Apart
Rearrangement Probe (Vysis, Abbott, Abbott Park, IL, USA) that consists of a mixture of two
FISH DNA probes were used for gene amplification. For FISH studies, 4-um-thick sections of
tumor tissue taken on coated slides were used, and after deparaffination, the slides were treated
with protease. Denaturation of DNA was carried out by immersing the slides in denaturing
solution (70% formamide) at 72 degree centigrade for 5 minutes. For hybridization, 10 uL of
probe mixture was applied on the target area, and the slide was incubated at 37 degree
centigrade overnight. After post-hybridization washes, 10 uL of DAPI (4′,6-diamidino-2-
phenylindole) counterstain was applied and a cover slip was placed. The next day, the cover slip
was removed, and the slide washed was in a salt/detergent solution to remove any of the
probes that should not bind to chromosomes. A differently colored fluorescent dye was added
to the slide to stain all of the chromosomes so that they may then be viewed using a fluorescent
light microscope. In a normal cell that lacks t(11;22)(q24;q12) in the EWSR1 gene region, a two
fusion signal pattern is observed owing to two intact copies of EWSR1. In positive cases with
t(11;22)(q24;q12), one fusion and two separate signals (one green and one red) as a result of
breakage pattern were seen (Figure 2).
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FIGURE 2: Photograph of one of our positive cases for t(11;22)
(q24;q12). Fusion signals (fused green and red signals) are
seen in tumor cells (indicated by arrow).
The disease-free survival was determined by reviewing hospital records.
Statistical Analysis
Data were analyzed using Statistical Package For Social Sciences (SPSS) Version 25 IBM Corp.,
Armonk, NY, USA). Mean and standard deviation were computed for quantitative variables, and
frequency and percentage were calculated for qualitative variables. Fisher’s exact test was
applied to check association. Kaplan-Meier test was also applied for disease-free survival
analysis. P-values ≤ 0.05 were considered as significant.
Results
There were 30 (69.8%) male patients and 13 (30.2%) female patients with a mean age of
18.23±9.57 years. Most of the patients were less than 18 years of age. Mean tumor size and
disease-free survival were 7.48±4.36 cm and 48.11±31.08 months, respectively. Bone was the
most commonly involved site (22; 51.2%) followed by soft tissue (17; 39.5%) and parenchymal
organs (4; 9.3%), as shown in Figure 3.
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FIGURE 3: Distribution of sites of involvement of Ewing’s
sarcoma
In our study, 88.4% of patients were found to be FISH-positive for t(11;22)(q24;q12). Detailed
characteristics of patients are shown in Table 1.
 Characteristic  N (%)
Age (years)
Mean±SD  18.23±9.57
Groups  
<18 years 22 (51.2)
18-35 years 19 (44.2)
>35 years 2 (4.7)
Tumor size (cm)
Mean±SD  7.48±4.36
Groups  
≤3 cm 8 (18.6)
3.1-8 cm 19 (44.2)
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>8 cm 16 (37.2)
Disease-free survival (months)
Mean±SD  48.11±31.08
Groups  
≤12 months 4 (9.3)
13-48 months 18 (41.9)
>48 months 21 (48.8)
Gender
Male 30 (69.8)
Female 13 (30.2)
Site
Bone  22 (51.2)
Soft tissue 17 (39.5)
Parenchymal organs 4 (9.3)
FISH for t(11;22)(q24;q12)
Positive 38 (88.4)
Negative 5 (11.6)
TABLE 1: Clinicopathological characteristics of the study population
SD, standard deviation; FISH, fluorescence in situ hybridization
We found no significant association of FISH-positive t(11;22)(q24;q12) with gender (p=0.0301),
age group (p=0.261), tumor size (p=0.580), disease-free survival (p=0.103) and site (p=1.000), as
presented in Table 2.
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  FISH, n (%)
p-Value
 Characteristic  Positive Negative
Gender
Male 25 (65.8) 5 (100)
0.301
Female 13 (34.2) 0 (0)
Age group
<18 years 20 (52.6) 2 (40)
0.26118-35 years 17 (44.7) 2 (40)
>35 years 1 (2.6) 1 (20)
Tumor size
≤3 cm 8 (21.1) 0 (0)
0.5803.1-8 cm 17 (44.7) 2 (40)
>8 cm 13 (34.2) 3 (60)
Disease-free survival
≤12 months 2 (5.3) 2 (40)
0.10313-48 months 17 (44.7) 1 (20)
>48 months 19 (50) 2 (40)
Site
Bone 19 (50) 3 (60)
1.000Soft tissue 15 (39.5) 2 (40)
Parenchymal organs 4 (10.5) 0 (0)
TABLE 2: Association of translocation t(11;22)(q24;q12) positivity with
clinicopathological characteristics
FISH, fluorescence in situ hybridization
Fisher exact test was applied. P ≤ 0.05 was considered as significant.
Similarly, no significant association of tumor size with disease-free survival was seen as shown
in Figure 4.
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FIGURE 4: Association of tumor size with disease-free survival
Discussion
In this study, we found a significant proportion of cases of ES to harbor characteristic
translocation t(11;22)(q24;q12). On the other hand, the presence or absence of this
translocation does not seem to impact the prognosis. Moreover, we did not find any significant
association of tumor size with disease-free survival in our patients.
Correctly identifying and diagnosing small round blue cell tumors is a pathological dilemma
and specific diagnosis sometimes become very difficult [7,8]. Differential diagnosis largely
depends on age and site. For instance, if the location is bone, especially near knee, then small
cell osteosarcoma becomes the most important tumor to rule out. On the other hand, in the
retroperitoneal location, neuroblastoma and desmoplastic small round cell tumor are the most
important differentials. Similarly in adults, Merkel cell carcinoma and metastatic
neuroendocrine carcinoma become the important differential diagnosis. Embryonal
rhabdomyosarcoma remains the most important differential diagnosis at all sites. IHC is the
most useful tool to narrow down differentials in these circumstances [9]. We only included
those cases of ES in our study that have unequivocal IHC profile, i.e., all tumors were positive
with CD99 and FLI1, some show focal synaptophysin immunoreactivity, and all were negative
with CKAE1/AE3, desmin, myogenin, LCA, and TdT immunostains. Still 12% of these cases
lacked translocation t(11;22)(q24;q12). This represents the presence of some variant
translocations that involves the EWSR1 gene on 22q12 chromosomal region, such as t(21;22),
(q22;q12), t(7;22)(p22;q12), or t(2;22)(q33;q12), that result in different fusion products, such as
EWSR1-ERG, EWSR1-ETV1, or EWSR1-FEV, respectively [10]. On the other hand, whether
these cases represents recently defined Ewing’s-like sarcoma tumors cannot be excluded with
confirmation without further molecular analysis [11].
We view our study with a few limitations. Most importantly, we did not investigate the
frequency of variant translocations involving the EWSR1 gene, which we think may be present
in the remaining 12% of our cases that lacked the translocation. Moreover, FISH break-apart
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probe cannot differentiate between different EWSR1-FLI1 fusion proteins, i.e., type 1 and type
2, which have shown to have some prognostic significance in different studies [12,13].
Conclusions
We found 88% frequency of characteristic ES translocation, i.e., t(11;22)(q24;q12), in our study,
and this signifies the role of molecular studies in cases difficult to diagnose on routine
histopathology and IHC. On the other hand, we did not find any prognostic role associated with
the presence of this translocation. Finally, no prognostic significance of tumor size was seen in
our cases.
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